Ultragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Applicatio...
Grifols , a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has finished recruiting the second cohort of...
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapa...
Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) t...
Merck known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved WELIREG® ...
3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positio...
AltaPointe Health, a leading provider of behavioral health services in Alabama, is making strides in addressing substance use disorders among wo...
TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first oral resolution film (ODF) of apixaban. Th...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...
Theratechnologies Inc., a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Admi...
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...
© 2025 Biopharma Boardroom. All Rights Reserved.
